Articles from SinoMab BioScience Limited
By SinoMab BioScience Limited · Via ACN Newswire · April 9, 2025

HONG KONG, Dec 19, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Company was awarded the "Most Valuable Pharmaceutical and Medical Company" at the "7th Hong Kong Golden Stocks Awards Ceremony" held in Hangzhou today.
By SinoMab BioScience Limited · Via ACN Newswire · December 19, 2022

By SinoMab BioScience Limited · Via ACN Newswire · March 14, 2022

By SinoMab BioScience Limited · Via ACN Newswire · February 17, 2022

By SinoMab BioScience Limited · Via ACN Newswire · February 7, 2022

By SinoMab BioScience Limited · Via ACN Newswire · January 11, 2022

By SinoMab BioScience Limited · Via ACN Newswire · November 30, 2021

By SinoMab BioScience Limited · Via ACN Newswire · November 26, 2021